1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6C6A90B1A2B91279F0025863900495843
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-pharma-digital-transformation-turning-point-medical-commercial-leaders-patient-engagement-speaker-programs-internal-engagement?opendocument
18
19opendocument
203.232.96.22
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Digital Technology » Cross-Functional Digital Transformation

Pharma’s Digital Transformation Turning Point for Medical and Commercial Leaders: Patient Engagement, Speaker Programs and Internal Engagement

ID: 5655


Features:

19 Info Graphics

16 Data Graphics

310+ Metrics

24 Narratives


Pages/Slides: 43


Published: 2020


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Pharma’s Digital Transformation Turning Point for Medical and Commercial Leaders: Patient Engagement, Speaker Programs and Internal Engagement”

STUDY OVERVIEW

While the COVID-19 pandemic disrupted nearly every aspect of the biopharma engagement model, it also sped up the much-needed digital transformation of the industry.

In the struggle to adapt, many companies have accelerated their adoption of digital solutions. However, they continue to face numerous challenges in transforming the business to better support healthcare stakeholders for years to come.

This Best Practices, LLC compendium draws upon 10 of our primary benchmark studies to uncover the most critical digital transformation strategies and programs being initiated across medical and commercial operational fronts in response to the COVID-19 pandemic.

This study probes the various approaches towards digital transformation adopted by forward-looking biopharma companies spanning critical areas including internal stakeholder engagement, speaker programs management, and patient engagement. It spotlights the key challenges and recommendations for biopharma leaders seeking to maximize performance and aid the digital growth of their own organization.

KEY TOPICS

  • Virtual engagement with patients
  • Managing speaker programs
  • Technology for engagement with internal stakeholders

KEY METRICS
  • How have you shifted your focus to caring for and engaging with patients since the pandemic has turned all social interactions to virtual technologies?
  • For the time periods listed, indicate what percentage of your programs were/are being done live, virtual, and taped for on-demand
  • Due to the emergence of the global pandemic, how has usage of the listed metrics for measuring success of your patient advocacy activities and relationships changed? What is the effectiveness of these metrics?
  • How frequently are you reaching out to advocacy partners to provide support around access or information?
  • Please identify the actions you are utilizing to improve virtual speaker programs and which is the most effective
  • What role/function is key to future success in utilizing virtual speaker programs and physician advisory boards?
  • How frequently are you using the various modes of technology to support internal stakeholder communication?
  • How effective are your modes of technology in communicating with your internal stakeholders?

SAMPLE KEY FINDINGS
  • Utilization of Speaker Program Formats: Eight in 10 of the speaker programs in 2019 were conducted live face-to-face. During COVID-19, programs were all virtual or taped. Post-COVID-19, nearly 50% of all programs are expected to remain virtual while 38% will revert to face-to-face events. The percentage of taped programs will also have increased in the future.

METHODOLOGY

This Best Practices, LLC compendium draws upon 10 of our primary benchmark studies of over 200 biopharma executives from 178 life sciences companies to reveal the most effective digital strategies, tools and approaches being implemented by forward-looking Medical and Commercial leaders.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biotech; Medical Device; Biopharmaceutical; Laboratories; Clinical Research; Manufacturing; Consumer Products; Consulting; Technology; Communications; Computer Software; Telecommunications; Research; Medical; Professional Services; Science; Marketing


Companies Profiled:
Abbott; AbbVie; ADC Therapeutics; Advanced Accelerator Applications; AeroGen; Inc.; Agios; Aimmune Therapeutics; Alcon Laboratories; Align Technology; Alkem; Alkermes; Allergan; Almirall; Alnylam Pharmaceuticals; AMAG Pharmaceuticals; Amgen; Amicus Therapeutics; Apellis Pharmaceuticals; Aptus Clinical; Arena Pharmaceuticals; Ascend Therapeutics; Ascensia; Asklepion Pharmaceuticals; LLC; Aspen Pharmacare; Astellas; AstraZeneca; Atara Biotherapeutics; Avadel Pharmaceuticals; Avanir; Avant Healthcare; Avantor Performance Materials; Baxter Healthcare; Bayer; BioDelivery Sciences International; Biofrontera; Biogen; Boehringer Ingelheim; Bracco Diagnostics Inc.; Braeburn; B. Braun; Canopy Growth; Cara Therapeutics; Cascadia Drug Development Group; Catalyst Pharma; Celyad; Chiesi; Cipla; Cofactor Group; Consensus Orthopedics; CSL Behring; Daiichi Sankyo; DBV Tehcnologies; Deciphera Pharmaceuticals; Dendreon Pharmaceuticals LLC; DiaSorin; Eagle Pharmaceuticals; EHOB; Inc; Eisai; EMD Serono; eNeura Therapeutics; Ethypharm; EyePoint Pharmaceuticals; FerGene; Ferozsons Laboratories Limited; Ferring Pharmaceuticals; Frankel Advisory Group LLC; Galderma; GE Healthcare; Genmab; Getz Pharma; Greenwich Biosciences; Grifols; Grünenthal; Guerbet; Halloran Consulting Group; Helsinn; Horizon Therapeutics; IDbyDNA; Idorsia; Ipsen; Iridex; Ironwood; Joerns Healthcare; Johnson & Johnson; Kala Pharmaceuticals; Kaleo; Karyopharm Therapeutics; Kiniksa Pharmaceuticals; Kyowa Kirin; Leica Biosystems; LeMaitre Vascular; LEO Pharma; Lundbeck; Lupin; Mayne Pharma; Medacta USA; Medexus Pharmaceuticals; Medicure; MedinCell; MEDiSTRAVA; Medrobotics; Medtronic; Melinta Therapeutics; Merck; Merck KGaA; Milestone Pharmaceuticals; Mint Pharmaceuticals Inc.; Mirador Global LP; Mission Bio; Monebo Technologies; Nabriva Therapeutics; Nestle Health Science; Nevakar; NexGen Healthcare Communications; Nobio; Novartis; Novo Nordisk; Nuvisan; Ora; Osmotica Pharmaceuticals; OTSUKA; Panacea Biotec; Paratek Pharmaceuticals; Pfizer; Piramal Group; Prime Global; Proteus Digital Health; Purdue Pharma; QED Therapeutics; Retrophin; Rigel Pharmaceuticals; Roche; Samumed; Sandoz; Sanofi; Sanofi Genzyme; Sanofi Pasteur; Santen; Santhera Pharmaceuticals; Sarah Cannon; Scilex Pharmaceuticals; Servier; Shionogi Inc.; Sivantos Pte. Ltd.; SK Life Science; Smith & Nephew; SomaGenics Inc; Stgilesmedical London & Berlin; Straumann; Sumitovant BioPharma; Sunovion; Supernus; Surrozen; Syneos Health; Takeda Pharmaceuticals; Tecan; TerSera Therapeutics; TG Therapeutics; The Medical Affairs Company; The Stem; Theravance; Thermo Fisher Scientific; Think Surgical; Thompson Surgical Instruments; UCB Pharma; United BioSource; Vertex Pharmaceuticals; Vifor Pharma; ViiV Healthcare; Visioneering Technologies Inc.; Wellspect HealthCare; West 53rd St Digital; Worldwide Clinical Trials; XACT Robotics; XG Sciences; Zeiss Pharma; Zosano Pharma; Zydus Cadila

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.